Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Novartis Ag ADR (NY: NVS ) 109.35 +0.95 (+0.88%) Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Novartis Ag ADR < Previous 1 2 3 4 5 6 7 8 9 ... 42 43 Next > JP Morgan's Bullish View On This Chinese Biotech, Says Pullback Creates Entry Point February 06, 2024 BeiGene's JP Morgan coverage highlights upside in valuation post-pullback. Brukinsa's success and Tevimbra's potential add to the optimism. Overweight rating, $185 price target. Via Benzinga Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B February 06, 2024 Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tulmimetostat. Via Benzinga Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion February 05, 2024 Novartis will add to its cancer treatment pipeline with via the German biotech. Via Investor's Business Daily Drug Maker AbbVie Stock Sees RS Rating Jump To 81 February 05, 2024 AbbVie stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 78 to 81. Via Investor's Business Daily Why Is MorphoSys (MOR) Stock Up 50% Today? February 05, 2024 News of a potential takeout bid for any company usually leads to a big surge. That's what investors are seeing today with MOR stock. Via InvestorPlace MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer February 05, 2024 Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold... Via Benzinga Earnings Outlook For Novartis January 30, 2024 Via Benzinga 3 Fabulous Dividend Stocks to Buy in February February 04, 2024 These stocks offer great dividends and more. Via The Motley Fool Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations February 02, 2024 The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. Via Benzinga Topics Economy Exposures Interest Rates Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review February 02, 2024 The Dow led the major indexes higher. Big techs diverged on results. Via Investor's Business Daily Topics Economy Stocks Exposures Interest Rates US Equities Novartis Ag (NVS) Q4 2023 Earnings Call Transcript January 31, 2024 NVS earnings call for the period ending December 31, 2023. Via The Motley Fool Topics Earnings Exposures Financial Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session January 31, 2024 Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD reported fourth-quarter non-GAAP earnings per share of 77 cents per share on... Via Benzinga Teva Sinks On Lackluster Profit Outlook Despite Walloping Quarterly Projections January 31, 2024 Teva Pharmaceutical easily beat fourth-quarter views, but its 2024 profit guidance left something to be desired. Via Investor's Business Daily Why Is European Pharma Giant Novartis Stock Trading Lower Today? January 31, 2024 Novartis Q4 2023 sales reach $11.42 billion, up 8%. Strong growth in key drugs, Entresto, Kisqali, Kesimpta, Cosentyx, and Pluvicto. Core operating income at $3.8 billion. Via Benzinga Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser January 31, 2024 The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook. Via Benzinga Topics Economy Exposures Interest Rates Alphabet Reports Q4 Results, Joins AMD, Tesla And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session January 31, 2024 U.S. stock futures were mostly lower this morning, with the Nasdaq futures falling more than 200 points on Wednesday. Via Benzinga Earnings Scheduled For January 31, 2024 January 31, 2024 Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion. Via Benzinga 3 Hidden Healthcare Stocks Poised for a Breakout This Year January 30, 2024 As the market preferences start to switch toward stable and defensive names like healthcare, these stocks could help your portfolio. Via InvestorPlace Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? January 29, 2024 An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending. Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence AbbVie Stock Moves With Rising Relative Strength, Still Room To Grow January 24, 2024 AbbVie shows improving price performance, earning an upgrade to its IBD Relative Strength Rating Via Investor's Business Daily Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer' January 24, 2024 FDA issues classwide black box warning for CAR-T therapies due to T-cell cancer risk. Drops Gilead's cell therapy from the list. Via Benzinga Exposures Product Safety Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment January 23, 2024 In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies. Via Benzinga Exposures Product Safety Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week January 13, 2024 Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will... Via Talk Markets Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst January 12, 2024 Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed... Via Benzinga Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review January 12, 2024 The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut. Via Investor's Business Daily Topics ETFs Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition January 11, 2024 Novartis AG (NYSE: NVS) has decided to step back from pursuing the Cytokinetics Inc (NASDAQ: CYTK) acquisition, dealing a blow to the potential deal with the Via Benzinga Bullish Continuation In '24? 3 Market Areas To Watch January 10, 2024 This article discusses 3 market areas that should outperform dramatically over the next 12 months... Via Talk Markets What's Been Happening With Cytokinetics Stock? January 09, 2024 Cytokinetics, Incorporated (NASDAQ: CYTK) shares are trading lower on Tuesday, pulling back from Monday strength. Via Benzinga Why Is Heart Failure Drug-Focused Cytokinetic Stock Trading Higher Today? January 08, 2024 Cytokinetics Inc (NASDAQ: CYTK) shares are trading higher after a report on potential takeover talks with Novartis AG (NYSE: NVS). Via Benzinga Cytokinetics Rockets 14% As Novartis Reportedly Nears A Buyout Deal January 08, 2024 The company is working on a treatment for a disease that can lead to heart failure. Via Investor's Business Daily < Previous 1 2 3 4 5 6 7 8 9 ... 42 43 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
